| Dr Michael David Hardison, DC | |
|
1624 E Seltice Way, Post Falls, ID 83854-7022 | |
| (208) 777-0128 | |
| (208) 773-9600 |
| Full Name | Dr Michael David Hardison |
|---|---|
| Gender | Male |
| Speciality | Chiropractic |
| Experience | 28 Years |
| Location | 1624 E Seltice Way, Post Falls, Idaho |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215091863 | NPI | - | NPPES |
| 807387600 | Medicaid | ID | |
| C2532 | Other | ID | BLUE CROSS OF IDAHO |
| 000010156505 | Other | ID | REGENCE BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | CHIA964 (Idaho) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hardison-walz Pc | 9032150420 | 2 |
News Archive
Synthetic biology, and particularly DNA synthesis, is transforming diagnosis and treatment of disease, and may yet play a key role in halting the COVID-19 pandemic.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed an innovative drug-delivery system in which tiny particles called nanodiamonds are used to carry chemotherapy drugs directly into brain tumors.
Rep. Barbara Lee (D-Calif.) and Sens. Chris Coons (D-Del.), Marco Rubio (R-Fla.) and Mike Enzi (R-Wyo.) on Wednesday at the XIX International AIDS Conference in Washington, D.C., joined former Senate Majority Leader Bill Frist (R-Tenn.) for a panel discussion on bipartisanship "focusing on sustaining the engagement of the U.S. Congress in order to demonstrate and encourage continued U.S. leadership in the fight against global AIDS," the Center for Global Health Policy's "Science Speaks" blog reports.
The Texas Department on Aging has officially launching a "Texas Cares" website - http://www.txcares.org - to help older Texans and people with disabilities get information that may help them obtain their prescription drugs.
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
› Verified 7 days ago
| Provider Name | Hardison-walz Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1861682353 PECOS PAC ID: 9032150420 Enrollment ID: O20050516000887 |
News Archive
Synthetic biology, and particularly DNA synthesis, is transforming diagnosis and treatment of disease, and may yet play a key role in halting the COVID-19 pandemic.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed an innovative drug-delivery system in which tiny particles called nanodiamonds are used to carry chemotherapy drugs directly into brain tumors.
Rep. Barbara Lee (D-Calif.) and Sens. Chris Coons (D-Del.), Marco Rubio (R-Fla.) and Mike Enzi (R-Wyo.) on Wednesday at the XIX International AIDS Conference in Washington, D.C., joined former Senate Majority Leader Bill Frist (R-Tenn.) for a panel discussion on bipartisanship "focusing on sustaining the engagement of the U.S. Congress in order to demonstrate and encourage continued U.S. leadership in the fight against global AIDS," the Center for Global Health Policy's "Science Speaks" blog reports.
The Texas Department on Aging has officially launching a "Texas Cares" website - http://www.txcares.org - to help older Texans and people with disabilities get information that may help them obtain their prescription drugs.
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael David Hardison, DC 1624 E Seltice Way, Post Falls, ID 83854-7022 Ph: (208) 777-0128 | Dr Michael David Hardison, DC 1624 E Seltice Way, Post Falls, ID 83854-7022 Ph: (208) 777-0128 |
News Archive
Synthetic biology, and particularly DNA synthesis, is transforming diagnosis and treatment of disease, and may yet play a key role in halting the COVID-19 pandemic.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed an innovative drug-delivery system in which tiny particles called nanodiamonds are used to carry chemotherapy drugs directly into brain tumors.
Rep. Barbara Lee (D-Calif.) and Sens. Chris Coons (D-Del.), Marco Rubio (R-Fla.) and Mike Enzi (R-Wyo.) on Wednesday at the XIX International AIDS Conference in Washington, D.C., joined former Senate Majority Leader Bill Frist (R-Tenn.) for a panel discussion on bipartisanship "focusing on sustaining the engagement of the U.S. Congress in order to demonstrate and encourage continued U.S. leadership in the fight against global AIDS," the Center for Global Health Policy's "Science Speaks" blog reports.
The Texas Department on Aging has officially launching a "Texas Cares" website - http://www.txcares.org - to help older Texans and people with disabilities get information that may help them obtain their prescription drugs.
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
› Verified 7 days ago
Dr. Matthan Wheeler, DC Chiropractor Medicare: May Accept Medicare Assignments Practice Location: 3904 E Mullan Ave Ste C, Post Falls, ID 83854 Phone: 208-981-0093 Fax: 208-981-0125 | |
Longevity Chiropractic Pllc Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 761 N Thornton St, Suite A, Post Falls, ID 83854 Phone: 208-777-7701 | |
Bridgewater Chiropractic And Soft Tissue Center Pllc Chiropractor Medicare: Medicare Enrolled Practice Location: 640 N Thornton St, Post Falls, ID 83854 Phone: 208-262-8166 | |
Richard Mason Stewart Iii, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 1643 E Tango Ln Unit 157, Post Falls, ID 83854 Phone: 208-252-5052 | |
Dr. Scott Nathan Crawford, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 1109 E Polston Ave, Post Falls, ID 83854 Phone: 208-777-4000 Fax: 208-777-4033 | |
Atlast Chiropractic, Pc Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 1624 E Seltice Way Ste B, Post Falls, ID 83854 Phone: 208-777-0128 | |
Dr. Richard Alan Hauser, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 614 E Seltice Way, Suite A, Post Falls, ID 83854 Phone: 208-777-1638 Fax: 208-777-9100 |